SMARCA4 Mutation clinical trials at UCSF
1 research study open to eligible people
SMARCA4 mutation changes genes that control cell growth. UCSF is running a trial to test PRT7732, a medicine for solid tumors with this mutation. Researchers measure how the medicine behaves in the body and its safety in patients.
Showing trials for
PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
open to eligible people ages 18 years and up
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
San Francisco, California and other locations
Last updated: